NCT03961334 - MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention | Biotech Hunter

Enrollment

620

Participants

Timeline

Start Date

December 5, 2019

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2026

Conditions

Stroke, Ischemic

Interventions

DRUG

Dabigatran

150mg 2x/d

DRUG

Apixaban

5mg 2x/d

DRUG

Edoxaban

60mg 1x/d

DRUG

Aspirin

100mg 1x/d

DRUG

Clopidogrel

75mg 1x/d

Trial Locations (14)

3010

RECRUITING

University Hospital of Bern/Inselspital, Bern

4031

RECRUITING

University Hospital of Basel, Basel

5001

RECRUITING

Kantonsspital Aarau, Department of Neurology, Aarau

6900

RECRUITING

Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale, Lugano

8032

NOT_YET_RECRUITING

Klinik Hirslanden, Zurich

8091

RECRUITING

University Hospital of Zurich, Department of Neurology, Zurich

8401

NOT_YET_RECRUITING

Kantonsspital Winterthur, Winterthur

9007

RECRUITING

Kantonsspital St.Gallen, Sankt Gallen

12462

RECRUITING

Attikon University Hospital, Athens

41009

RECRUITING

Hospital Universitario Virgen Macarena, Seville

41013

RECRUITING

Campus Hospital Universitario Virgen del Rocío, Seville

0424

NOT_YET_RECRUITING

Oslo University Hospital - Ullevål, Oslo

08041

RECRUITING

Hospital de la Santa Creu I Sant Pau, Barcelona

G51 4TF

NOT_YET_RECRUITING

Queen Elizabeth University Hospital, Glasgow

All Listed Sponsors

collaborator

Swiss National Science Foundation

OTHER

lead

University of Zurich

OTHER